Clinical trials: Post-Treatment
Type 2 Diabetes Mellitus (T2DM), Overweight , Obesity
A Study to Evaluate Different Administration Conditions and the Food Effect of MWN109 Tablets in Chinese Participants
This is a randomized, open-label, multiple-dose study to evaluate the effects of different volumes of administration water, post-dose fasting duration, and high-fat diet on the pharmacokinetics of the 15 mg dose of MWN109 tablets…
- Trial name
- NCT07801326
- Testing
- MWN109 Tablets
- Where
- China
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Healthy
A Multiple Increasing Dose Safety and Tolerability Study After Inhalation Administration of BIIX 1 XX in Healthy Male Volunteers
The objective of the present study is to obtain information about the safety and tolerability of multiple increasing doses of BIIX 1 XX and to obtain preliminary pharmacokinetic data
- Trial name
- NCT02198313
- Testing
- BIIX 1 XX - D1, BIIX 1 XX - D2, BIIX 1 XX - D3
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Migraine
Positron Emission Tomography (PET) Study of Brain Calcitonin Gene-Related Peptide (CGRP) Receptor Occupancy After Telcagepant Administration (MK-0974-067)
The purpose of this study is to determine the receptor occupancy (RO) associated with telcagepant (MK-0974) administration based on displacement of [11C]MK-4232 from the CGRP receptors in the brain using PET.
- Trial name
- NCT01315847
- Testing
- telcagepant, [11C]MK-4232
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Paroxysmal Nocturnal Hemoglobinuria
Efficacy and Safety of HRS-5965 in Patients With PNH Who Are Still Anemia After Anti-C5 Antibody Treatment
This trial is a multi-center, single-arm, open-label phase III clinical trial. A total of approximately 35 patients with paroxysmal nocturnal hemoglobinuria who remained anemic despite stable use of C5 complement inhibitor…
- Trial name
- NCT06715943
- Testing
- HRS-5965 capsule
- Where
- 2 sites in China
- Volunteers
- 39 people
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
Multiple Sclerosis, Relapsing
Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab
Open-label, prospective, single-arm, multi-center study to assess disease activity and biomarker of neuronal damage in minority patients (self-identified Black or African American (AA) and Hispanic/Latino (HA) patients with…
- Trial name
- NCT04377555
- Testing
- Ocrelizumab
- Where
- 28 sites in United States, Kenya and 1 more
- Volunteers
- 179 people
- Sponsor
- Genentech, Inc.
Non-small Cell Lung Cancer
Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose
To determine whether dose escalation can provide a better survival to patients who failed with icotinib at routine dose.
- Trial name
- NCT01465243
- Testing
- Icotinib
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Cardiogenic Shock, STEMI
Incorporating Supersaturated Oxygen in Shock
A multi-center, prospective randomized (1:1) pilot and feasibility study to evaluate the safety and feasibility of supersaturated oxygen (SSO2) therapy delivered for 60 minutes selectively into the culprit coronary artery of…
- Trial name
- ISO-SHOCK (NCT04876040)
- Testing
- SSO2 Downstream System, PCI + Impella
- Where
- 7 sites in United States
- Sponsor
- TherOx
Osteoporosis, Post-Menopausal
PTH Comparison in Post Menopausal Women
Compare in postmenopausal women with established osteoporosis the effect of treatment with teriparatide 20 micrograms/day subcutaneous with the effect of salmon calcitonin 100 IU/day subcutaneous on change in lumbar spine BMD.
- Trial name
- NCT00543218
- Testing
- teriparatide 20 micrograms/day subcutaneous, calcitonin 100 IU/day subcutaneous
- Where
- 4 sites in Taiwan
- Volunteers
- 63 people
- Sponsor
- Eli Lilly and Company
Post-Operative Nausea and Vomiting (PONV)
Single Dose Safety Study for Compound to Treat Post-Operative Nausea and Vomiting (PONV)
The purpose of this study is to describe the safety and tolerability and pharmacokinetics of a single intravenous administration of the new, Sulfobutyl Ether-7-Beta-Cyclodextrin (Captisol™) based, formulation in Healthy Adult…
- Trial name
- NCT01290133
- Testing
- GW597599
- Where
- Australia
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Accenture
Post-Stroke Spasticity, Cerebrovascular Accident
Study of GSK1358820 In Patients With Post-Stroke Lower Limb Spasticity
This is a study to confirm the superior efficacy of GSK1358820 over placebo in patients with equinus deformity associated with post-stroke lower limb spasticity using the Modified Ashworth Scale (MAS) ankle score.
- Trial name
- NCT00460655
- Testing
- GSK1358820
- Where
- 20 sites in Japan
- Volunteers
- 120 people
- Sponsor
- GlaxoSmithKline
Carotid Artery Stenosis
PMCF Study of Precise Pro Rx for Carotid Artery Disease
The purpose of this study is to evaluate long-term clinical safety and performance of the PRECISE PRO RX Nitinol Stent System to treat stenotic lesions of the carotid arteries.
- Trial name
- REAL-PRECISE (NCT07204678)
- Testing
- PRECISE PRO Rx Nitinol Stent System
- Where
- 4 sites in Austria, France and 1 more
- Volunteers
- 199 people
- Sponsor
- Cordis US Corp.
Ocular Inflammation and Pain After Cataract Surgery
A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery
This is a Phase 2a, 2-part study (designated Parts A and B) that will evaluate APP13007 dose strength and dosing frequency in a randomized double-masked fashion for comparison to the respective matching vehicle placebo.
- Trial name
- NCT04089735
- Testing
- APP13007, 0.05%, APP13007, 0.1%
- Where
- 9 sites in United States
- Volunteers
- 165 people
- Sponsor
- Formosa Pharmaceuticals, Inc.
Moderate to Severe Plaque-type Psoriasis
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
The purpose of this study is to demonstrate efficacy of secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.
- Trial name
- FEATURE (NCT01555125)
- Testing
- secukinumab 150 mg, secukinumab 300 mg
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 177 people
- Sponsor
- Novartis Pharmaceuticals
Cardiovascular Diseases
A Multicenter Observational Registry to Evaluate Safety and Performance of Vivo ISAR (SECURE Global Registry)
The objective of this post marketing observational registry is to evaluate clinical outcomes (safety and performance) in an all-comers population with coronary artery disease (CAD) treated with the Polymer Free Sirolimus Eluting…
- Trial name
- NCT06412250
- Where
- 32 sites in India, Italy and 2 more
- Volunteers
- 2,000 people
- Sponsor
- Translumina Therapeutics Pvt Ltd.
Muscular Atrophy, Spinal
A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec
In this study, researchers will learn more about the safety and effects of BIIB115, also known as salanersen. Specifically, researchers will learn more about how salanersen works in babies who have already been treated with…
- Trial name
- STELLAR-2 (NCT07444450)
- Testing
- Salanersen
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Biogen
Healthy
The Food Effect on Pharmacokinetics of DA-8010 After a Single Administration of DA-8010 2.5 mg or 5 mg in Healthy Subjects
This is a randomized, open-label, single-dose, 4-way crossover phase 1 study to evaluate the food effect on pharmacokinetics of DA-8010 after a single administration of DA-8010 2.5 mg or 5 mg under fasting and fed states in…
- Trial name
- NCT04686825
- Testing
- DA-8010 2.5mg (Fasting), DA-8010 2.5mg (Fed), DA-8010 5mg (Fasting)
- Where
- South Korea
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Healthy
To Evaluate the PK, PD, Safety and Drug Tolerance of JW0302 in Healthy Volunteers
1. To evaluate the pharmacokinetic and pharmacodynamics characteristics after administration of Reference Drug or Test Drug in healthy volunteers under fasting conditions 2.
- Trial name
- NCT05784155
- Testing
- Test Drug(JW0302) or Reference Drug(C2206)
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- JW Pharmaceutical
Hypothyroidism
Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation
The purpose of this study is to investigate the effect of switching participants taking levothyroxine to a new sodium formulation.
- Trial name
- NCT01916304
- Testing
- Levothyroxine sodium new formulation
- Where
- Belgium
- Volunteers
- 101 people
- Sponsor
- Takeda
Pain
Investigation of Rate + Extent of Excretion of Radioactivity in Urine +Faeces After Oral Administration of [14C]AZD2066
The aim of this study is to get information about absorption, distribution, metabolism and excretion as well as the tolerability and safety of AZD2066 in healthy male volunteers.
- Trial name
- NCT00829088
- Testing
- AZD2066
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Non-erosive Reflux Disease
A Study to Investigate the Pharmacodynamic Effect After Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population
The purpose of this study is to investigate the pharmacodynamic effect of omeprazole n a Japanese non-erosive reflux disease population
- Trial name
- NCT00259051
- Testing
- Omeprazole
- Where
- 13 sites in Japan
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.